Evaluating the Impact of ClinGen Variant Curation Expert Panel Criteria Specifications on Variant Interpretation across Multiple Genes.

Reclassification of 1,223 variants in ACMG SF v3.3 genes after applying ClinGen VCEP gene-specific criteria vs. generic ACMG/AMP criteria

1,223 variants in ACMG Secondary Findings v3.3 genes with available ClinGen VCEP criteria were classified using both approaches: generic ACMG/AMP criteria and gene-specific VCEP criteria. The comparison reveals significant reclassifications, notably from VUS to P/LP or vice versa. VCEP criteria reduce VUS rates and improve inter-laboratory concordance, validating the gene-specific expert panel approach as a classification standard.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

This study quantifies what molecular biologists know empirically: gene-specific VCEP criteria significantly reclassify VUS compared to generic ACMG/AMP criteria. The direct impact on practice is strong — particularly for ACMG SF3.3 genes where actionable secondary findings are at stake. A solid argument for accelerating VCEP development across all priority diagnostic genes.

Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 2/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 9/10